Nevro reports preliminary Q1 revenue roughly $96.3M, consensus $94.99M

Preliminary, unaudited first quarter 2023 worldwide revenue is expected to be approximately $96.3 million, an increase of 10% as reported and 11% on a constant currency basis compared to the first quarter of 2022. Worldwide PDN indication sales are expected to represent approximately $15.6 million in the first quarter of 2023, an increase of 160% compared to the first quarter of 2022. Preliminary, unaudited first quarter 2023 U.S. revenue is expected to be approximately $82.3 million, reflecting growth of 12% over the first quarter of 2022.